Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xtant Medical Holdings (XTNT) EBIT Margin (2016 - 2025)

Xtant Medical Holdings has reported EBIT Margin over the past 16 years, most recently at 7.64% for Q3 2025.

  • Quarterly EBIT Margin rose 2116.0% to 7.64% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 11.27% through Sep 2025, up 2357.0% year-over-year, with the annual reading at 2.91% for FY2024, 821.0% up from the prior year.
  • EBIT Margin was 7.64% for Q3 2025 at Xtant Medical Holdings, down from 13.06% in the prior quarter.
  • Over five years, EBIT Margin peaked at 21.51% in Q4 2024 and troughed at 14.14% in Q1 2022.
  • The 5-year median for EBIT Margin is 9.84% (2024), against an average of 5.67%.
  • Year-over-year, EBIT Margin plummeted -1591bps in 2021 and then surged 3505bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 13.7% in 2021, then rose by 18bps to 11.29% in 2022, then fell by -20bps to 13.54% in 2023, then skyrocketed by 259bps to 21.51% in 2024, then crashed by -64bps to 7.64% in 2025.
  • Per Business Quant, the three most recent readings for XTNT's EBIT Margin are 7.64% (Q3 2025), 13.06% (Q2 2025), and 3.23% (Q1 2025).